FDA Commissioner Makary defends agency’s decision on Replimune’s drug
May 5 (Reuters) - U.S. Food and Drug Administration Commissioner Dr. Marty Makary on Tuesday defended the agency's decision to not approve Replimune's drug for advanced skin cancer.
"If you read our what we call our complete response letter, you will see the details of... Read More.


